Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Nerdwallet Inc (NRDS) vs Sanofi SA (SNY) Price & Performance

Nerdwallet IncTrade

Price performance (Past 24H)

Key statistics

Nerdwallet Inc vs Sanofi SA — how do they compare? Nerdwallet Inc trades at $9.45 (market cap $625.17M), while Sanofi SA trades at $43.61 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 166.8× Nerdwallet Inc's market cap, and Sanofi SA pays a 5.55% dividend while Nerdwallet Inc pays none. Which is the better fit depends on your goals.

NRDSSNY
Market Cap
$625.17M$104.30B
Sector
FinancialsHealth
52-Week High
$15.93$52.34
52-Week Low
$7.58$41.33
Enterprise Value
$539.47M$124.19B
Dividend Yield
5.55%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Nerdwallet Inc

NerdWallet (NRDS) trades at $9.48, down 3.27% today, amid mixed signals. The stock shows bullish technical momentum with a 10.87 P/E ratio indicating potential undervaluation. Revenue grew to $836.6M in 2025, with net income reaching $48.7M, though Q2 2026 earnings missed expectations. Positive analyst sentiment includes a 66.66% buy rating, with news highlighting a 27.9% upside potential from Zacks Investment Research on August 10, 2026.

Outlook is cautiously optimistic with strong profitability margins and cash flow growth, but risks include organic-search pressure and competitive threats. The stock's valuation and recent momentum suggest upside, though investors must monitor earnings consistency and market volatility.

Sanofi SA

SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.

Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Nerdwallet Inc

Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.

Read more on NRDS

About Sanofi SA

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Read more on SNY